Home » Authors » Omar Ford

Articles by Omar Ford

Silver: Secret weapon against MRSA, other bacterial infections

Nov. 19, 2007

Pfizer to pay Nektar $135 million fee for abandoning Exubera

Nov. 14, 2007

For tonsil/adenoid removal, PITA procedures offer faster recovery

Nov. 13, 2007

BioTime, Argonne form partnership for therapeutic hypothermia study

Nov. 7, 2007

Market/technology updates: Study data favors bypass surgery over PCI/stenting

Nov. 1, 2007

MichBio effort tries 'virtual' for boost to its life sciences

Nov. 1, 2007

New Ventures: Device/drug combo to be ExThera focus

Nov. 1, 2007

Study shows bypass surgery more effective than stenting

Oct. 30, 2007

Thompson: change or 'collapse' the options facing healthcare

Oct. 29, 2007

Kickbacks are eroding trust, increasingly ‘losing juries’

Oct. 26, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...